Skip to content
Roboearth – Lifestyle
Author:
Zymeworks Inc.
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
March 30, 2026
Zymeworks Announces Participation in Upcoming Investor Conferences
March 24, 2026
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting
March 18, 2026
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
March 18, 2026
←
Previous Page
1
2